Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Incyte (INCY) Weakness Seen Related to OPZELURA Sample 'Texture Issues' - Mizuho
November 2, 2021 11:02 AM EDTMizuho Securities analyst Mara Goldstein weighed in on Incyte (NASDAQ: INCY) following Q3 results and its earnings call. The analyst believes the weakness is likely related to management's comment on a texture issue associated with OPZELURA' (ruxolitinib cream) samples for atopic dermatitis (AD) and is under investigation... More
Incyte (INCY) Tops Q3 EPS by 46c
November 2, 2021 7:16 AM EDTIncyte (NASDAQ: INCY) reported Q3 EPS of $1.18, $0.46 better than the analyst estimate of $0.72. Revenue for the quarter came in at $813 million versus the consensus estimate of $738.52 million.
... More